AbCellera Biologics Inc. (ABCL) shareholders
Close on Nov 17, 2026Market cap $3.38BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Carl L.G. Hansen Joint filing with Thermopylae Holdings Ltd. (19.20%) | 60,740,524 | 20.60% | 13G (passive) amendment | Dec 31, 2023 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (10.80%), Julian C. Baker (10.80%) and 1 more | 33,012,138 | 10.80% | 13G (passive) amendment | Apr 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABCL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 33,012,138 | 10.77% | $259.15M | +2,736,200 | 1.30% |
| Capital World Investors | 13,588,349 | 4.43% | $106.67M | +227,253 | 0.01% |
| Two Sigma Investments, LP | 10,437,431 | 3.40% | $81.93M | −124,634 | 0.06% |
| TD Waterhouse Canada Inc. | 9,568,149 | 3.12% | $72.62M | +3,490 | 0.19% |
| Bank Of America Corp /De/ | 6,141,539 | 2.00% | $48.21M | +3,141,603 | 0.00% |
| UBS Asset Management Americas Inc | 4,317,206 | 1.41% | $33.89M | −3,258,270 | 0.01% |
| ArrowMark Colorado Holdings LLC | 4,105,095 | 1.34% | $32.22M | – | 1.34% |
| BlackRock, Inc. | 3,805,309 | 1.24% | $29.87M | −234,927 | 0.00% |
| Driehaus Capital Management LLC | 2,864,729 | 0.93% | $22.49M | −1,160,050 | 0.13% |
| Tudor Investment Corp Et Al | 2,063,191 | 0.67% | $16.20M | −210,298 | 0.02% |
| Marshall Wace, Llp | 1,902,191 | 0.62% | $14.93M | +1,542,508 | 0.01% |
| UBS Group AG | 1,870,633 | 0.61% | $14.68M | −2,338,419 | 0.00% |
| Morgan Stanley | 1,669,014 | 0.54% | $13.10M | −555,815 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,587,870 | 0.52% | $12.47M | New | 0.00% |
| Citadel Advisors LLC | 1,586,512 | 0.52% | $12.45M | +225,407 | 0.00% |
| National Bank Of Canada /Fi/ | 1,233,014 | 0.40% | $9.68M | +1,231,621 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 1,039,927 | 0.34% | $8.16M | New | 0.00% |
| Renaissance Technologies LLC | 990,929 | 0.32% | $7.78M | −519,700 | 0.01% |
| Counterpoint Mutual Funds LLC | 971,643 | 0.32% | $7.63M | New | 0.75% |
| State Street Corp | 731,362 | 0.24% | $5.74M | +1,149 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 151 | 116M | 37.9% | 39 / 36 | 54 / 26 | 17M | 25M |
| Q1 2026 | 138 | 124M | 40.5% | 20 / 53 | 35 / 26 | 29M | 13M |
| Q4 2025 | 144 | 109M | 35.4% | 31 / 50 | 38 / 28 | 24M | 19M |
| Q3 2025 | 142 | 104M | 34.0% | 35 / 44 | 35 / 21 | 15M | 19M |
| Q2 2025 | 128 | 108M | 35.3% | 19 / 38 | 43 / 18 | 10M | 37M |
| Q1 2025 | 129 | 136M | 44.4% | 12 / 33 | 51 / 27 | 34M | 11M |
| Q4 2024 | 146 | 114M | 37.2% | 27 / 45 | 39 / 17 | 18M | 8M |
| Q3 2024 | 139 | 106M | 34.6% | 19 / 52 | 34 / 27 | 17M | 22M |
| Q2 2024 | 148 | 115M | 37.4% | 20 / 37 | 48 / 25 | 10M | 13M |
| Q1 2024 | 154 | 122M | 39.8% | 27 / 47 | 41 / 15 | 9M | 7M |
| Q4 2023 | 143 | 120M | 39.1% | 26 / 48 | 35 / 19 | 8M | 8M |
| Q3 2023 | 138 | 120M | 39.1% | 19 / 38 | 39 / 51 | 7M | 12M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
25 funds held ABCL in Q2 2026, 20% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ABCL | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 13,228,596 | 4.31% | $103.84M | 0.11% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,656,204 | 0.54% | $13.00M | 0.14% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,053,900 | 0.34% | $8.27M | 0.06% | Jun 30, 2026 |
| Counterpoint Quantitative Equity ETF | 971,643 | 0.32% | $7.63M | 2.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio Developed World ex-US ETF | 564,320 | 0.18% | $4.43M | 0.01% | Jun 30, 2026 |
| iShares Genomics Immunology and Healthcare ETF | 508,935 | 0.17% | $2.91M | 1.52% | Jul 31, 2026 |
| SMALLCAP World Fund | 359,753 | 0.12% | $2.82M | 0.11% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 339,622 | 0.11% | $2.10M | 0.04% | May 29, 2026 |
| Driehaus Micro Cap Growth Fund | 246,560 | 0.08% | $1.94M | 0.32% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 180,133 | 0.06% | $1.11M | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) International Small Cap ETF | 166,042 | 0.05% | $1.30M | 0.15% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index ETF | 134,674 | 0.04% | $830.94K | 0.01% | May 31, 2026 |
| Small Cap Value Fund | 123,712 | 0.04% | $971.14K | 0.14% | Jun 30, 2026 |
| Adara Smaller Companies Fund | 120,162 | 0.04% | $741.40K | 0.09% | May 31, 2026 |
| Avantis U.S. Equity ETF | 64,811 | 0.02% | $399.88K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carl L. G. Hansen | Chief Executive Officer, Director, 10% owner | 56,984,009 | 18.59% | Jan 5, 2026 |
| Veronique Lecault | Chief Technology Officer, Director | 9,340,044 | 3.05% | Jan 5, 2026 |
| Andrew Booth | Chief Financial Officer | 622,359 | 0.20% | Nov 16, 2026 |
| Tryn Stimart | Chief Legal Officer | 500 | 0.00% | Jan 5, 2026 |
| Michael R. Hayden | Director | 1,491,642 | 0.49% | Aug 24, 2026 |
| John S. Montalbano | Director | 256,000 | 0.08% | Aug 18, 2026 |
| Victor Sandor | Director | – | – | Jul 6, 2026 |
| Lynn Seely | Director | – | – | Jul 6, 2026 |
| Stephen Quake | Director | 1,100,436 | 0.36% | Jun 12, 2026 |
| Andrew Lo | Director | 86,938 | 0.03% | Jun 16, 2025 |
| Holdings Ltd. Thermopylae | 10% owner | 56,069,662 | 18.29% | Nov 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Andrew Booth Chief Financial Officer | Nov 13, 2026 | Gift | −50,000 | – | – | 491,400 |
| Andrew Booth Chief Financial Officer | Nov 13, 2026 | Option exercise | +50,000 | $0.32 | $16.08K | 541,400 |
| Holdings Ltd. Thermopylae 10% owner | Nov 13, 2026 | Gift | −125,000 | – | – | 56,069,662 |
| Andrew Booth Chief Financial Officer | Nov 13, 2026 | Buy | +8,600 | $11.33 | $97.44K | 491,400 |
| Holdings Ltd. Thermopylae 10% owner | Nov 12, 2026 | Buy | +60,565 | $11.54 | $698.92K | 56,194,662 |
| Michael R. Hayden Director | Aug 24, 2026 | Buy | +53,613 | $10.64 | $570.44K | 1,373,397 |
| John S. Montalbano Director | Aug 18, 2026 | Buy | +10,000 | $11.03 | $110.30K | 251,000 |
| Andrew Booth Chief Financial Officer | Aug 14, 2026 | Buy | +37,200 | $10.32 | $383.90K | 482,800 |
| Michael R. Hayden Director | Aug 12, 2026 | Buy | +46,387 | $10.37 | $481.03K | 1,319,784 |
| Michael R. Hayden Director | Aug 11, 2026 | Gift | −50,000 | – | – | 1,273,397 |
| Andrew Booth Chief Financial Officer | Jun 3, 2026 | Option exercise | +250,000 | $0.19 | $47.50K | 445,600 |
| John S. Montalbano Director | May 14, 2026 | Buy | +20,000 | $4.77 | $95.40K | 241,000 |
| Holdings Ltd. Thermopylae 10% owner | Feb 27, 2026 | Buy | +38,000 | $3.44 | $130.72K | 56,134,097 |
| Andrew Booth Chief Financial Officer | Feb 27, 2026 | Buy | +42,600 | $3.42 | $145.69K | 195,600 |
| Holdings Ltd. Thermopylae 10% owner | Feb 26, 2026 | Buy | +177,457 | $3.27 | $580.28K | 56,096,097 |
| Holdings Ltd. Thermopylae 10% owner | Dec 18, 2025 | Gift | −225,000 | – | – | 55,918,640 |
| John S. Montalbano Director | Nov 26, 2025 | Buy | +50,000 | $3.57 | $178.50K | 221,000 |
| Holdings Ltd. Thermopylae 10% owner | Mar 11, 2025 | Buy | +343,631 | $2.16 | $742.24K | 56,143,640 |
| John S. Montalbano Director | Mar 10, 2025 | Buy | +25,000 | $2.30 | $57.50K | 171,000 |
| John S. Montalbano Director | Mar 6, 2025 | Buy | +60,000 | $2.34 | $140.40K | 146,000 |
| Holdings Ltd. Thermopylae 10% owner | Dec 4, 2024 | Gift | −286,000 | – | – | 55,800,009 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Nov 25, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 898,000 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Sep 20, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 841,875 |
| Holdings Ltd. Thermopylae 10% owner | Aug 29, 2024 | Buy | +283,516 | $2.61 | $739.98K | 56,086,009 |
| Veronique Lecault Chief Operating Officer, Director | Jun 21, 2024 | Option exercise | +83,334 | $0.19 | $15.83K | 2,123,456 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | May 31, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 785,750 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Feb 26, 2024 | Option exercise | +56,125 | $2.70 | $151.54K | 729,625 |
| Holdings Ltd. Thermopylae 10% owner | Dec 19, 2023 | Gift | −210,000 | – | – | 55,802,493 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Nov 23, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 673,500 |
| John S. Montalbano Director | Nov 8, 2023 | Buy | +10,000 | $4.46 | $44.60K | 86,000 |
| John S. Montalbano Director | Nov 6, 2023 | Buy | +20,000 | $4.64 | $92.80K | 76,000 |
| Michael R. Hayden Director | Sep 22, 2023 | Buy | +20,000 | $4.91 | $98.20K | 1,323,397 |
| Veronique Lecault Chief Operating Officer, Director | Sep 12, 2023 | Buy | +20,000 | $5.19 | $103.80K | 2,040,122 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Aug 24, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 617,375 |
| Michael R. Hayden Director | Aug 8, 2023 | Buy | +30,000 | $5.90 | $177.00K | 1,303,397 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | May 26, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 561,250 |
| Andrew Booth Chief Financial Officer | May 26, 2023 | Buy | +14,500 | $6.85 | $99.33K | 153,000 |
| Holdings Ltd. Thermopylae 10% owner | May 26, 2023 | Buy | +153,000 | $6.52 | $997.56K | 56,012,493 |
| Veronique Lecault Chief Operating Officer, Director | May 5, 2023 | Option exercise | +250,000 | $0.19 | $47.50K | 2,020,122 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Feb 22, 2023 | Option exercise | +56,125 | $2.70 | $151.54K | 505,125 |
| Andrew Booth Chief Financial Officer | Dec 20, 2022 | Option exercise | +50,000 | $0.19 | $9.50K | 188,500 |
| Andrew Booth Chief Financial Officer | Dec 20, 2022 | Gift | −50,000 | – | – | 138,500 |
| Holdings Ltd. Thermopylae 10% owner | Dec 16, 2022 | Buy | +85,102 | $10.10 | $859.53K | 55,859,493 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Nov 18, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 449,000 |
| Holdings Ltd. Thermopylae 10% owner | Oct 31, 2022 | Gift | −70,000 | – | – | 55,774,391 |
| Holdings Ltd. Thermopylae 10% owner | Aug 19, 2022 | Buy | +200,000 | $11.46 | $2.29M | 55,844,391 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Aug 18, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 392,875 |
| Holdings Ltd. Thermopylae 10% owner | Jun 14, 2022 | Buy | +9,173 | $8.05 | $73.84K | 55,644,391 |
| Holdings Ltd. Thermopylae 10% owner | Jun 13, 2022 | Buy | +54,915 | $8.03 | $440.97K | 55,635,218 |
| Holdings Ltd. Thermopylae 10% owner | Jun 6, 2022 | Buy | +64,545 | $7.50 | $484.09K | 55,580,303 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | May 18, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 336,750 |
| Veronique Lecault Chief Operating Officer, Director | May 16, 2022 | Buy | +200,000 | $6.34 | $1.27M | 1,770,122 |
| Holdings Ltd. Thermopylae 10% owner | May 13, 2022 | Buy | +300,000 | $7.26 | $2.18M | 55,515,758 |
| Andrew Booth Chief Financial Officer | May 12, 2022 | Buy | +85,000 | $5.79 | $492.15K | 138,500 |
| Holdings Ltd. Thermopylae 10% owner | May 12, 2022 | Buy | +1,408,468 | $6.41 | $9.03M | 55,215,758 |
| John S. Montalbano Director | Mar 4, 2022 | Buy | +10,000 | $8.54 | $85.40K | 56,000 |
| John S. Montalbano Director | Mar 1, 2022 | Buy | +20,000 | $9.05 | $181.00K | 46,000 |
| Veronique Lecault Chief Operating Officer, Director | Feb 28, 2022 | Buy | +230,789 | $8.66 | $2.00M | 1,570,122 |
| Carl L. G. Hansen Chief Executive Officer, Director, 10% owner | Feb 22, 2022 | Option exercise | +56,125 | $2.70 | $151.54K | 280,625 |
| Andrew Booth Chief Financial Officer | Dec 10, 2021 | Gift | −500,000 | – | – | 53,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AbCellera Biologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 82,773 shares on Aug 26, 2026 over the last 90 days.
See a number that looks wrong?